JP7826477B2 - 疾患又は障害の治療のためのナフチリジノン誘導体 - Google Patents

疾患又は障害の治療のためのナフチリジノン誘導体

Info

Publication number
JP7826477B2
JP7826477B2 JP2024529834A JP2024529834A JP7826477B2 JP 7826477 B2 JP7826477 B2 JP 7826477B2 JP 2024529834 A JP2024529834 A JP 2024529834A JP 2024529834 A JP2024529834 A JP 2024529834A JP 7826477 B2 JP7826477 B2 JP 7826477B2
Authority
JP
Japan
Prior art keywords
dichloro
methyl
naphthyridin
chloro
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024529834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543107A5 (enExample
JP2024543107A (ja
Inventor
チャン，アトウッド，キム
リウ，ドンレイ
ポイカート，ステファン
ゲ，ヘン
ガイ，ユ
チャン，シンジャン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024543107A publication Critical patent/JP2024543107A/ja
Publication of JP2024543107A5 publication Critical patent/JP2024543107A5/ja
Application granted granted Critical
Publication of JP7826477B2 publication Critical patent/JP7826477B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024529834A 2021-11-23 2022-11-21 疾患又は障害の治療のためのナフチリジノン誘導体 Active JP7826477B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163282492P 2021-11-23 2021-11-23
US63/282,492 2021-11-23
CN2022128601 2022-10-31
CNPCT/CN2022/128601 2022-10-31
PCT/IB2022/061218 WO2023094965A1 (en) 2021-11-23 2022-11-21 Naphthyridinone derivatives for the treatment of a disease or disorder

Publications (3)

Publication Number Publication Date
JP2024543107A JP2024543107A (ja) 2024-11-19
JP2024543107A5 JP2024543107A5 (enExample) 2025-08-25
JP7826477B2 true JP7826477B2 (ja) 2026-03-09

Family

ID=84370237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529834A Active JP7826477B2 (ja) 2021-11-23 2022-11-21 疾患又は障害の治療のためのナフチリジノン誘導体

Country Status (29)

Country Link
US (2) US12084442B2 (enExample)
EP (2) EP4436662B1 (enExample)
JP (1) JP7826477B2 (enExample)
KR (1) KR20240110040A (enExample)
CN (1) CN118382623A (enExample)
AR (1) AR127698A1 (enExample)
AU (1) AU2022396087A1 (enExample)
CA (1) CA3235682A1 (enExample)
CL (1) CL2024001524A1 (enExample)
CO (1) CO2024006398A2 (enExample)
CR (1) CR20240216A (enExample)
DK (1) DK4436662T3 (enExample)
DO (1) DOP2024000096A (enExample)
EC (1) ECSP24038829A (enExample)
ES (1) ES3054973T3 (enExample)
FI (1) FI4436662T3 (enExample)
HR (1) HRP20251558T1 (enExample)
IL (1) IL312689A (enExample)
JO (1) JOP20240119A1 (enExample)
LT (1) LT4436662T (enExample)
MA (1) MA67325B1 (enExample)
MX (1) MX2024006176A (enExample)
PE (1) PE20241328A1 (enExample)
PL (1) PL4436662T3 (enExample)
PT (1) PT4436662T (enExample)
RS (1) RS67492B9 (enExample)
TW (1) TW202329949A (enExample)
UY (1) UY40025A (enExample)
WO (1) WO2023094965A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260015867A (ko) * 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018073788A1 (en) 2016-10-21 2018-04-26 Novartis Ag Naphthyridinone derivatives and their use in the treatment of arrhythmia
WO2019241311A1 (en) 2018-06-11 2019-12-19 Northeastern University Selective ligands for modulation of girk channels

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (en) 1904-11-07 1905-03-14 William Waid Paddock Pressure filter
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6683113B2 (en) 1999-09-23 2004-01-27 Pharmacia Corporation (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
HUP0301335A3 (en) 2000-04-12 2006-02-28 Novartis Ag Combination of organic compounds
DK1537114T3 (da) 2002-08-07 2006-11-13 Novartis Ag Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
CN100447142C (zh) 2002-11-18 2008-12-31 诺瓦提斯公司 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP2007530550A (ja) 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP5179174B2 (ja) 2004-05-28 2013-04-10 ノバルティス ファーマ アーゲー アルドステロンシンターゼ阻害剤としてのテトラヒドロ−イミダゾ［１，５−ａ］ピリジン誘導体
US7612088B2 (en) 2004-05-28 2009-11-03 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
CA2568164A1 (en) 2004-05-28 2005-12-15 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
WO2006005726A2 (en) 2004-07-09 2006-01-19 Speedel Experimenta Ag Heterocyclic compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
TW200804378A (en) 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
US20090156875A1 (en) 2006-04-04 2009-06-18 Takafumi Tomioka Methane separation method, methane separation apparatus, and methane utilization system
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
CA2660701A1 (en) 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
EA200900811A1 (ru) 2006-12-18 2009-12-30 Новартис Аг Имидазолы в качестве ингибиторов альдостеронсинтазы
KR20090090395A (ko) 2006-12-18 2009-08-25 노파르티스 아게 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도
EP2094669A2 (en) 2006-12-18 2009-09-02 Novartis AG 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
RU2009139811A (ru) 2007-03-29 2011-05-10 Новартис АГ (CH) Гетероциклические спиросоединения
HK1201455A1 (en) 2012-01-27 2015-09-04 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
KR20230022829A (ko) 2020-03-03 2023-02-16 트웬티에잇-세븐, 인크. Rna 결합 단백질 또는 rna 변형 단백질을 표적으로 하는 화합물
WO2022074567A1 (en) 2020-10-06 2022-04-14 Novartis Ag Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018073788A1 (en) 2016-10-21 2018-04-26 Novartis Ag Naphthyridinone derivatives and their use in the treatment of arrhythmia
WO2019241311A1 (en) 2018-06-11 2019-12-19 Northeastern University Selective ligands for modulation of girk channels

Also Published As

Publication number Publication date
CA3235682A1 (en) 2023-06-01
PL4436662T3 (pl) 2026-02-16
TW202329949A (zh) 2023-08-01
UY40025A (es) 2023-06-15
HRP20251558T1 (hr) 2026-01-16
KR20240110040A (ko) 2024-07-12
DOP2024000096A (es) 2024-06-30
PT4436662T (pt) 2025-12-16
US12084442B2 (en) 2024-09-10
EP4436662A1 (en) 2024-10-02
US20230203032A1 (en) 2023-06-29
MA67325B1 (fr) 2025-11-28
RS67492B9 (sr) 2026-02-27
ES3054973T3 (en) 2026-02-09
JP2024543107A (ja) 2024-11-19
IL312689A (en) 2024-07-01
EP4656240A1 (en) 2025-12-03
JOP20240119A1 (ar) 2024-05-23
AU2022396087A1 (en) 2024-04-11
CN118382623A (zh) 2024-07-23
AR127698A1 (es) 2024-02-21
PE20241328A1 (es) 2024-06-26
FI4436662T3 (fi) 2025-12-12
WO2023094965A1 (en) 2023-06-01
CO2024006398A2 (es) 2024-07-18
CL2024001524A1 (es) 2024-11-08
LT4436662T (lt) 2025-12-29
MX2024006176A (es) 2024-06-11
CR20240216A (es) 2024-07-01
ECSP24038829A (es) 2024-06-28
DK4436662T3 (da) 2025-12-22
US20250214989A1 (en) 2025-07-03
RS67492B1 (sr) 2025-12-31
EP4436662B1 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
JP7394074B2 (ja) 治療用化合物
WO2018234978A1 (en) Substituted 5-cyanoindole compounds and uses thereof
WO2015095256A1 (en) Antidiabetic substituted heteroaryl compounds
JP7030776B2 (ja) アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
CN113227093A (zh) 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法
EP4673431A1 (en) Hydroquinazoline derivatives for the treatment of a disease or disorder
JP7826477B2 (ja) 疾患又は障害の治療のためのナフチリジノン誘導体
KR20230011981A (ko) 치환된 트리사이클릭 아미드, 이의 유사체, 및 이를 사용하는 방법
HK40130208A (en) Naphthyridinone derivatives for the treatment of a disease or disorder
HK40109683A (en) Naphthyridinone derivatives for the treatment of a disease or disorder
HK40109683B (en) Naphthyridinone derivatives for the treatment of a disease or disorder
US20240391941A1 (en) Naphthyridinone derivatives for the treatment of a disease or disorder
WO2026093992A1 (en) Benzothiazole and benzoimidazole derivatives for the treatment of a disease or disorder
HK40058222A (en) A crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing
HK40021223B (en) Bicyclic compounds and their use in the treatment of cancer
HK1232169B (en) Substituted 4-phenylpiperidines, their preparation and use
HK1232169A1 (en) Substituted 4-phenylpiperidines, their preparation and use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250815

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260225

R150 Certificate of patent or registration of utility model

Ref document number: 7826477

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150